Skip to main content

Victoza FDA Approval History

Last updated by Judith Stewart, BPharm on June 17, 2019.

FDA Approved: Yes (First approved January 25, 2010)
Brand name: Victoza
Generic name: liraglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 2

Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Development timeline for Victoza

DateArticle
Jun 17, 2019Approval FDA Approves Victoza (liraglutide) for the Treatment of Pediatric Patients 10 Years or Older with Type 2 Diabetes
Aug 25, 2017Approval Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
Apr  9, 2012Approval Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia
Jan 26, 2010Approval FDA Approves Novo-Nordisk's Diabetes Drug Victoza
Apr  3, 2009Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
May 30, 2008Novo Nordisk Files for Regulatory Approval of Liraglutide in Both the US and Europe

See also

Victoza (liraglutide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer